Metastatic Breast Cancer Clinical Trials
Metastatic Breast Cancer clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for metastatic Breast Cancer. Corterve aggregates actively recruiting Metastatic Breast Cancer studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Metastatic Breast Cancer studies
- The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyNCT06377852PHASE3American Society of Clinical OncologyMetastatic Breast CancerChandler, Arizona
- Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.NCT06590857PHASE1, PHASE2RayzeBio, Inc.Metastatic Breast CancerPhoenix, Arizona
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521PHASE3Relay Therapeutics, Inc.PIK3CA MutationGilbert, Arizona
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsNCT06784193PHASE1Olema Pharmaceuticals, Inc.Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Gilbert, Arizona
- Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal MetastasisNCT02422641PHASE2Wake Forest University Health SciencesMetastatic Breast CancerBaltimore, Maryland
- A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast CancerNCT05534438PHASE2Memorial Sloan Kettering Cancer CenterOligometastatic Breast CarcinomaBasking Ridge, New Jersey
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerNCT06369285PHASE2Puma Biotechnology, Inc.Hormone Receptor Positive HER-2 Negative Breast CancerBirmingham, Alabama
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsNCT06625775PHASE1TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Solid Tumor, AdultDuarte, California
- A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerNCT07701941PHASE1, PHASE2Daiichi SankyoHormone Receptor PositiveLos Angeles, California
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadNCT06324357PHASE1, PHASE2Boehringer IngelheimMetastatic Breast CancerCerritos, California
- PRE-ISPY Phase I/II Oncology Platform ProgramNCT05868226PHASE1, PHASE2QuantumLeap Healthcare CollaborativeHER2-positive Breast CancerBirmingham, Alabama
- Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast CancerNCT06105684PHASE2University of Alabama at BirminghamMetastatic Breast CancerBirmingham, Alabama
Metastatic Breast Cancer trials by state
Metastatic Breast Cancer trials by metro
Frequently asked questions
- How do I find recruiting Metastatic Breast Cancer clinical trials?
- Browse the actively recruiting Metastatic Breast Cancer studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
- Are Metastatic Breast Cancer clinical trials free to join?
- Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
- Who can take part in a Metastatic Breast Cancer clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.